Tags

Type your tag names separated by a space and hit enter

Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Am J Psychiatry 2001; 158(9):1511-4AJ

Abstract

OBJECTIVE

The authors' goal was to conduct a double-blind trial of vitamin B(6) in the treatment of tardive dyskinesia in patients with schizophrenia.

METHOD

Fifteen inpatients with schizophrenia who met research diagnostic criteria for tardive dyskinesia were randomly assigned to treatment with either vitamin B(6) or placebo for 4 weeks in a double-blind crossover paradigm. The Extrapyramidal Symptom Rating Scale was used to assess patients weekly.

RESULTS

Mean scores on the parkinsonism and dyskinetic movement subscales of the Extrapyramidal Symptom Rating Scale were significantly better in the third week of treatment with vitamin B(6) than during the placebo period.

CONCLUSIONS

Vitamin B(6) appears to be effective in reducing symptoms of tardive dyskinesia.

Authors+Show Affiliations

Division of Psychiatry, Ministry of Health Be'er Sheva Mental Health Center, Faculty of Health Sciences Ben-Gurion University of the Negev, Israel. lernervld@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11532741

Citation

Lerner, V, et al. "Vitamin B(6) in the Treatment of Tardive Dyskinesia: a Double-blind, Placebo-controlled, Crossover Study." The American Journal of Psychiatry, vol. 158, no. 9, 2001, pp. 1511-4.
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(9):1511-4.
Lerner, V., Miodownik, C., Kaptsan, A., Cohen, H., Matar, M., Loewenthal, U., & Kotler, M. (2001). Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. The American Journal of Psychiatry, 158(9), pp. 1511-4.
Lerner V, et al. Vitamin B(6) in the Treatment of Tardive Dyskinesia: a Double-blind, Placebo-controlled, Crossover Study. Am J Psychiatry. 2001;158(9):1511-4. PubMed PMID: 11532741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. AU - Lerner,V, AU - Miodownik,C, AU - Kaptsan,A, AU - Cohen,H, AU - Matar,M, AU - Loewenthal,U, AU - Kotler,M, PY - 2001/9/5/pubmed PY - 2001/9/28/medline PY - 2001/9/5/entrez SP - 1511 EP - 4 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 158 IS - 9 N2 - OBJECTIVE: The authors' goal was to conduct a double-blind trial of vitamin B(6) in the treatment of tardive dyskinesia in patients with schizophrenia. METHOD: Fifteen inpatients with schizophrenia who met research diagnostic criteria for tardive dyskinesia were randomly assigned to treatment with either vitamin B(6) or placebo for 4 weeks in a double-blind crossover paradigm. The Extrapyramidal Symptom Rating Scale was used to assess patients weekly. RESULTS: Mean scores on the parkinsonism and dyskinetic movement subscales of the Extrapyramidal Symptom Rating Scale were significantly better in the third week of treatment with vitamin B(6) than during the placebo period. CONCLUSIONS: Vitamin B(6) appears to be effective in reducing symptoms of tardive dyskinesia. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/11532741/Vitamin_B_6__in_the_treatment_of_tardive_dyskinesia:_a_double_blind_placebo_controlled_crossover_study_ L2 - https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.158.9.1511?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -